Mobile
Votre recherche
Source: isrctn - Le promoteur: The Psoriasis and Psoriatic Arthritis Alliance (PAPAA) (UK)
The Psoriasis and Psoriatic Arthritis Alliance (PAPAA) (UK) MAJ Il y a 4 ans

Community pharmacists optimising treatment for patients with psoriasis Background and study aims Psoriasis is a long-term inflammatory skin condition that affects up to 2% of the people in the UK. There is no cure for psoriasis and the condition tends to come and go but once it has developed it is normally life-long. The majority of people with psoriasis need to use creams or ointments on a daily basis. This requires a high level of commitment yet research shows that many people don’t get enough advice from anyone on how to use them. As a result, psoriasis is often poorly managed by patients. In this study we want to see if advice given by community pharmacists can lead to better management of psoriasis and ultimately improvements in the severity of the condition. Who can participate? The study is open to anyone over the age of 18 who is prescribed creams or ointments to manage their psoriasis. What does the study involve? Patients who visit participating community pharmacies to collect their prescriptions for topical psoriasis treatments will be invited by the pharmacist or a member of staff to join the study. The study involves two consultations with the pharmacist. At the first appointment the pharmacist will use a specially designed guide to ask the person several questions to assess their understanding of psoriasis and if they know how to use their treatments. The pharmacist will also ask the person to complete two further questionnaires; one of these looks at the impact of psoriasis on their quality of life and the second asks them to rate the severity of their psoriasis. Both of these questionnaires have been used previously in research studies and are very quick and easy to complete. During the initial appointment the pharmacist will provide advice to help the person use their treatments properly. A second appointment will then be arranged for about 4 weeks later to go through the same initial questions to see if the person now has a better understanding of what to do with their treatments. The two questionnaires will also be repeated to see if the person’s quality of life is improved and if they think their psoriasis is less severe. What are the possible benefits and risks to participants? The benefits for the patients are that they should have a better understanding of their condition and how to manage it. It is also likely that improvements in both quality of life and disease severity will occur once the person knows more about how to use treatments properly. There are unlikely to be any risks associated with the study. Where is the study run from? The study will be run from participating pharmacies and is being co-ordinated by Robert Gordon University, Aberdeen. When is the study starting and how long it is expected to run for? We hope to start the study in September 2014 and it will continue until we have recruited and completed two interviews with 30 patients. Who is funding the study? The Psoriasis and Psoriatic Arthritis Alliance (UK). Who is the main contact? Dr Rod Tucker [email protected]

  • Pays Aucun
  • Organes Aucun
  • Spécialités Aucun
Essai clos aux inclusions
Plus d'informations